Expertise in
3
conditions

Dr. Stephen M. Schleicher

Tennessee Oncology PLLC
Nashville, TN
Expertise in
3
conditions
Specialties:Oncology | Hematology
Accepting New Patients
Offers Telehealth
Expertise in
3
conditions
OverviewInsuranceLocationsClinical Research

Overview

Stephen Schleicher is an Oncologist and a Hematologist in Nashville, Tennessee. Dr. Schleicher is highly rated in 3 conditions, according to our data. His top areas of expertise are Familial Colorectal Cancer, Lynch Syndrome, Colorectal Cancer, and Breast Cancer. Dr. Schleicher is currently accepting new patients.

His clinical research consists of co-authoring 45 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in MA
Hospital Affiliations
Tristar Summit Medical Center
Rhea Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  Oscar
  •  US Health and Life
  •  Humana

Locations

TENNESSEE ONCOLOGY PLLC
2004 Hayes St, Suite 350, Nashville, TN 37203
615-312-3333
Other Locations
RHEA MEDICAL CENTER
9400 Rhea County Hwy, Dayton, TN 37321
423-775-1121

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Active_not_recruiting
Publish Date: December 09, 2024
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Parallel-Group, Active and Placebo Controlled Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Extended Release Capsules for the Treatment of Inflammatory Lesions of Rosacea Over 16 Weeks.
A Multicenter, Randomized, Double-Blind, Parallel-Group, Active and Placebo Controlled Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Extended Release Capsules for the Treatment of Inflammatory Lesions of Rosacea Over 16 Weeks.
Enrollment Status: Completed
Publish Date: December 03, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 1
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: NKTR-358
Study Phase: Phase 1
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Drug
Study Drug: NFX-179
Study Phase: Phase 2
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Natroba™ (Spinosad) for the Treatment of Scabies
A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Natroba™ (Spinosad) for the Treatment of Scabies
Enrollment Status: Completed
Publish Date: May 21, 2021
Intervention Type: Other, Drug
Study Phase: Phase 3
View 8 Less Clinical Trials

45 Total Publications

Association of Participation in Medicare's Oncology Care Model With Spending, Utilization, and Quality Outcomes Among Commercially Insured and Medicare Advantage Members.
Association of Participation in Medicare's Oncology Care Model With Spending, Utilization, and Quality Outcomes Among Commercially Insured and Medicare Advantage Members.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 02, 2024
Similar Doctors
Expertise in
38
conditions
Dr. Adetola A. Kassim
Hematology | Oncology
Expertise in
38
conditions
Dr. Adetola A. Kassim
Hematology | Oncology

Vanderbilt University Medical Center

1301 22nd Ave S, 
Nashville, TN 
 (0.8 mi)
615-322-3000
Languages Spoken:
English, Yoruba
See accepted insurances
Accepting New Patients
Offers Telehealth

Adetola Kassim is a Hematologist and an Oncologist in Nashville, Tennessee. Dr. Kassim is highly rated in 38 conditions, according to our data. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kassim is currently accepting new patients.

Expertise in
28
conditions
Dr. Michael R. Savona
Hematology | Hematology Oncology | Oncology
Expertise in
28
conditions
Dr. Michael R. Savona
Hematology | Hematology Oncology | Oncology

Vanderbilt University Medical Center

1301 22nd Ave S, 
Nashville, TN 
 (0.8 mi)
615-322-3000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Savona is a Hematologist and a Hematologist Oncology provider in Nashville, Tennessee. Dr. Savona is highly rated in 28 conditions, according to our data. His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelofibrosis, and Bone Marrow Aspiration. Dr. Savona is currently accepting new patients.

Expertise in
13
conditions
Dr. Kristen K. Ciombor
Oncology | Hematology
Expertise in
13
conditions
Dr. Kristen K. Ciombor
Oncology | Hematology

Vanderbilt University Medical Center

1301 22nd Ave S, 
Nashville, TN 
 (0.8 mi)
615-322-3000
Languages Spoken:
English, Sign Language
See accepted insurances
Accepting New Patients
Offers Telehealth

Kristen Ciombor is an Oncologist and a Hematologist in Nashville, Tennessee. Dr. Ciombor is highly rated in 13 conditions, according to our data. Her top areas of expertise are Colorectal Cancer, Anal Cancer, Familial Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Gastrostomy. Dr. Ciombor is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile